Black Diamond Therapeutic... (BDTX)
2.24
-0.07 (-3.03%)
At close: Jan 14, 2025, 3:59 PM
2.10
-6.25%
Pre-market Jan 15, 2025, 08:48 AM EST
undefined% (undefined)
| Bid | 2.1 |
| Market Cap | 126.75M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -1.68 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.17 |
| Volume | 1,849,894 |
| Avg. Volume (20D) | 712,070 |
| Open | 2.19 |
| Previous Close | 2.31 |
| Day's Range | 2.08 - 2.28 |
| 52-Week Range | 1.91 - 7.66 |
| Beta | undefined |
About BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2020
Employees 54
Stock Exchange NASDAQ
Ticker Symbol BDTX
Analyst Forecast
According to 4 analyst ratings, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 591.96% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-5.46%
Black Diamond Therapeutics shares are trading high...
Unlock content with
Pro Subscription
4 months ago ·
Source
-12.44%
Black Diamond Therapeutics shares are trading lower. The company presented a poster analyzing real-world treatment outcomes for newly diagnosed non-small cell lung cancer patients with non-classical EGFR mutations at the ESMO Congress 2024
